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Abstract
Background: Coexistence of childhood asthma, eczema and allergic rhinitis is higher 
than can be expected by chance, suggesting a common mechanism. Data on allergic 
multimorbidity from a pan- European, population- based birth cohort study have been 
lacking. This study compares the prevalence and early- life risk factors of these dis-
eases in European primary school children.
Methods: In the prospective multicentre observational EuroPrevall- iFAAM birth co-
hort study, we used standardized questionnaires on sociodemographics, medical his-
tory, parental allergies and lifestyle, and environmental exposures at birth, 12 and 
24 months. At primary school age, parents answered ISAAC- based questions on cur-
rent asthma, rhinitis and eczema. Allergic multimorbidity was defined as the coexist-
ence of at least two of these.
Results: From 10,563 children recruited at birth in 8 study centres, we included data 
from 5,572 children (mean age 8.2 years; 51.8% boys). Prevalence estimates were as 
follows: asthma, 8.1%; allergic rhinitis, 13.3%; and eczema, 12.0%. Allergic multimor-
bidity was seen in 7.0% of the whole cohort, ranging from 1.2% (Athens, Greece) to 
10.9% (Madrid, Spain). Risk factors for allergic multimorbidity, identified with AICc, 
included family- allergy- score, odds ratio (OR) 1.50 (95% CI 1.32– 1.70) per standard 
deviation; early- life allergy symptoms, OR 2.72 (2.34– 3.16) for each symptom; and 
caesarean birth, OR 1.35 (1.04– 1.76). Female gender, OR 0.72 (0.58– 0.90); older sib-
lings, OR 0.79 (0.63– 0.99); and day care, OR 0.81 (0.63– 1.06) were protective factors.
Conclusion: Allergic multimorbidity should be regarded as an important chronic child-
hood disease in Europe. Some of the associated early- life factors are modifiable and 
may be considered for prevention strategies.
K E Y W O R D S
allergic multimorbidity, allergic rhinitis, asthma, children, eczema
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1  |  INTRODUC TION
Interest in multiple coexisting allergic diseases (allergic multimor-
bidity) has been increasing, and several recent studies address 
prevalence and risk factors focusing on childhood and adoles-
cence. Allergic multimorbidity is often defined as two or more al-
lergic diseases: asthma, allergic rhinitis and eczema. The German 
birth cohort Multicentre Allergy Study (MAS) found an allergic 
multimorbidity prevalence of 2% at age 9 in those with no family 
history, compared with 11% of those with at least one allergic par-
ent.1 The Mechanisms of the Development of ALLergy (MeDALL) 
meta- analysis showed a relatively high occurrence of coexisting 
asthma, allergic rhinitis and eczema in 4- and 8- year- old children 
in many European cohorts suggesting a common mechanism.2 In 
their combined data analysis, as well as in the Swedish BAMSE 
birth cohort,3 allergic multimorbidity prevalence increased with 
age up to adolescence.
The iFAAM study is a continuation of the EuroPrevall birth 
cohort study that recruited newborns in 2005– 20104,5 and com-
pleted its last follow- up assessment at 6– 10 years in eight European 
cities.6 It gives a unique opportunity to estimate the influence of 
prenatal and postnatal environmental, lifestyle and sociodemo-
graphic early- life factors on the prevalence of asthma (allergic and 
non- allergic), allergic rhinitis, eczema and allergic multimorbidity at 
primary school age in Europe, which is indeed the aim of the cur-
rent analysis.
2  |  METHODS
2.1  |  Study design, setting and population
The study design and baseline characteristic of the study population 
have been described in detail previously.4– 7 In summary, the prospective 
multicentre birth cohort study (funded by the European Commission) 
recruited 12,049 newborns in 2005– 2010 in 9 European centres 
(Figure 1). After a perinatal baseline interview, regular standardized 
parental telephone interviews were conducted at 12 and 24 months 
of age. Sociodemographics, medical history, parental allergies, parental 
lifestyle, dietary habits, environmental exposures and other potentially 
influential factors for developing allergies were assessed. Excluded 
were children born before 34 weeks, with a 5- min APGAR score <7, 
and parents with insufficient skills of the local language.4
During the years 2014– 2017, at primary school age, all the study 
centres except Milan participated in a follow- up assessment, iFAAM 
(also funded by the European Commission). Parents answered ques-
tions online, including questions on symptoms of current allergic 
diseases. A few parents who were unable or unwilling to access/
complete the questionnaire by themselves were invited to the study 
centre or questioned via telephone interviews.
Ethical approval was obtained individually for both study peri-
ods from the local ethics committee in each participating country. 
Informed parental consent was also obtained for each assessment, in 
written form for the early childhood period, and online at school age.
G R A P H I C A L  A B S T R A C T
Allergic multimorbidity (coexistence of asthma, eczema and allergic rhinitis) is common among European children at primary school age, with 
7% of study participants affected. Protective factors identified in the study include female sex, having older siblings and attending day care. 
Risk factors include history of allergic diseases in first- degree family members, early- age symptoms and caesarean birth.
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2.2  |  Key outcomes
The iFAAM questionnaire was based on stringent epidemiological 
definitions and validated and widely used questions in population- 
based cross- sectional childhood and teenage studies such as the 
International Study of Asthma and Allergies in Childhood (ISAAC 
project).8– 11
Current asthma at school age was defined as present if at least 
three of the following five parent- reported criteria were fulfilled: 
(a1) wheezing or whistling, (a2) breathing difficulties, (a3) dry cough 
at night, (a4) asthma medication, all in the past 12 months and (a5) 
doctor- diagnosed asthma ever. Asthma was also considered to be 
present if criteria (a4) and (a5) were both fulfilled without any of the 
three symptoms (a1– a3), indicating a well- managed disease.
Current allergic rhinitis at school age was defined as present if at 
least two of the following three criteria were fulfilled: (r1) sneezing, 
or a runny or blocked nose, without having a cold, (r2) nasal allergy/
hay fever medication, both in the past 12 months, and (r3) doctor- 
diagnosed allergic rhinitis or hay fever ever.
Current eczema at school age was defined as present if both of 
the following criteria were fulfilled: (e1) an itchy rash, which was 
intermittently coming and going, and (e2) doctor- diagnosed eczema/
atopic dermatitis ever.
Current allergic multimorbidity at school age was defined as pres-
ent if at least two of current asthma, allergic rhinitis and eczema 
were coexisting.
2.3  |  Definition of covariates
Many of the early- age covariates were simple yes- no questions: sex, 
caesarean- birth, child's and mother's antibiotics- at- birth, cows- milk- 
in- first- week, pets- at- home (cats/dogs), live- on- a- farm and mould in 
the house. Other early- age covariates require more explanation. 
Mothers- age is a simple continuous variable, parent- education is also 
continuous, sum of mother's and father's education codes, each of 
these in the range 1– 4 according to education level. Family- allergy- 
score at baseline is also a continuous variable and computed as pre-
viously described (Appendix S1).12 Breastfeeding is true if the child 
was breastfed for ≥6 months (possibly along with other feeding). 
Breastfeeding for ≥4 months was also evaluated. Vitamin- D was true 
if the child received daily vitamin D supplementation starting within 
the first 2 months. Older- siblings (dichotomous) is true if other chil-
dren, ≤10 years older, were living in the household. Day- care is true 
if the child attended day care before the age of 18 months for ≥8 h/
week with ≥2 other children. Pregnancy- smoking is true if the mother 
reported smoking ≥5 cigarettes/d during pregnancy. Smoking- at- 
home (dichotomous variable) is true if ≥10 cigarettes/d were smoked 
at home.
The continuous variable early- age- symptoms was defined as 
the sum of three dichotomous variables: symptoms associated 
with asthma, allergic rhinitis and eczema. The first of these is 1 
if the child had wheezing or whistling in the chest between 12 
and 24 months of age; otherwise, it is 0. The second is 1 if the 
child had at least 2 of the following 3 criteria before age 2: (1) 
sneezing, or a runny or blocked nose, without having a cold, (2) 
itchy, watery eyes and (3) doctor- diagnosed hay fever. The third 
is 1 if the child had an itchy rash or eczema that lasted for at least 
7 days, in the fold of the elbows, behind the knees, in front of the 
ankles, on the cheeks or around the neck, ears or eyes, before 
age 2.
A crucial variable considered was the study centre. This variable 
was treated as giving a multiplicative centre effect, as described in 
more detail in the statistics section below.
Finally, the iFAAM study included a question on current heavy 
traffic, which was the only school- age covariate considered.
2.4  |  Data processing and statistical analysis
Data were processed with Unix and MATLAB (version 9.3; The 
MathWorks Inc.). To assess the significance of covariates, a logis-
tic regression model was constructed, where centre effect was in-
cluded as a multiplicative factor:
F I G U R E  1  Flow chart of the population- based pan- European 
birth cohort study showing the EuroPrevall and iFAAM participants 
up to inclusion in the current analysis. The EuroPrevall study 
centre Milan did not participate in the iFAAM project. The 
eight participating cities were as follows: Reykjavík, Iceland; 
Southampton, UK; Amsterdam, the Netherlands; Berlin, Germany; 
Lodz, Poland; Vilnius, Lithuania; Madrid, Spain; and Athens, 
Greece. ‘Not in current study’ are children whose parents were not 
reachable or were not interested in participation at school age
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The covariates entering the model were selected using the AICc 
criterion (Akaike information criterion with correction). One advan-
tage of using AICc is that it is independent of (arbitrary) statistical 
significance levels: it selects the model with the smallest expected 
mean squared error.13 Forest plots were used to show 95% confi-
dence intervals.
Note that in the model all individuals weight equally, and there-
fore, the centres are effectively weighted by the participant count in 
each one, as in inverse probability weighting.14
3  |  RESULTS
3.1  |  Study prevalence of allergic diseases
Of 10,563 recruited children in the eight participating centres, 5572 
(52.8%) fulfilled the eligibility criteria listed in Section 2.1 (Figure 1). 
Table S1 shows a breakdown of the dropout by study centre. The 
participation in individual centres is shown in Figure 2. The children 
were aged between 6 and 10 years when the last parental question-
naire was answered. The allergic outcomes at school age were as fol-
lows: asthma, 8.1%; allergic rhinitis, 13.3%; eczema, 12.0%; allergic 
multimorbidity, 7.0%; and all three diseases, 1.3% (Table 1).
Odds = (center effect) × (effect of covariate 1) × (effect of covariate 2) ×…
F I G U R E  2  The eight centres of the population- based 
EuroPrevall- IFAAM birth cohort study, the number of children who 
participated in each one at the school- age follow- up assessment 
(in total 5572 children) and the proportion of these with allergic 
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The difference between the centres was considerable, with only 
1.2% allergic multimorbidity in Athens and 4.0% in Vilnius, reach-
ing 9.4– 10.9% in Amsterdam, Southampton, Lodz and Madrid, with 
Reykjavik and Berlin falling in- between. Asthma had the largest 
prevalence in Southampton, allergic rhinitis in Lodz and eczema in 
Madrid (Table 1).
3.2  |  Differences between non- participating and 
participating school- age children
Tables 2 and S1 show a summary of the covariates for the two 
groups: the 3212 children dropping out in the last step in Figure 1 
and the final study population for the current analysis. There 
were fewer day care children in the dropout group (two- tailed, 
p < .01), and that group also had fewer children with early- age 
symptoms of allergic diseases (p = .04). There were more smok-
ing at home, more pregnancy smoking, less breastfeeding, more 
dogs and more children but fewer mothers receiving antibiotics at 
birth, parent education level was lower (p < .01 for all), and there 
was less vitamin D supplementation in the non- participating 
group (p = .03).
3.3  |  Risk factors
The logistic regression model included six covariates for allergic mul-
timorbidity, selected according to AICc: family- allergy- score, early- 
age- symptoms, sex, caesarean- birth, older- siblings and day- care before 
18 months of age (Table 2, Figure 3). Female sex, older- siblings and 
TA B L E  2  Early- life covariates according to study centre. The table shows only covariates that AICc selected into the model for allergic 














Allergy- like symptoms before 
age 2 (%)
Wheezing Rhinitis Eczema
Participants in current study
Reykjavik 848 1.5 47.9 12.6 54.4 77.6 4.7 15.7 9.4 15.0
Southampton 350 1.7 44.3 31.7 43.7 45.4 1.1 10.3 10.6 16.3
Amsterdam 628 1.5 48.7 11.6 52.7 69.9 5.4 9.6 9.1 21.3
Berlin 970 1.4 47.9 32.1 36.3 66.0 3.3 10.1 6.0 12.7
Lodz 837 0.7 49.0 38.2 27.5 4.9 0.0 0.7 9.6 10.0
Vilnius 833 0.3 48.0 18.8 34.7 10.8 2.5 2.0 0.4 4.0
Madrid 589 1.0 48.9 3.2 42.1 61.6 10.4 2.4 2.5 12.1
Athens 517 0.7 46.8 44.7 40.6 10.4 8.5 2.7 6.8 5.8
Total 5572 1.1 48.0 23.9 40.8 43.9 4.2 6.8 6.6 11.8
Not participating 3212 1.0 48.2 22.9 43.1 35.9 6.0 6.2 5.6 10.2
Note: Family- allergy- score is standardized to have SD = 1. The table also shows a summary for the EuroPrevall children who did not participate in 
primary school- age follow- up assessment (iFAAM project). See section 2.3 for detailed definitions and Table S3 for other covariates. There is a 
significant difference (according to a two- tailed test at the 5% level), for day care, pregnancy smoking and all the early- age allergy- like symptoms 
(shown in bold italics).
F I G U R E  3  Odds ratios and 95% confidence intervals for protective factors (green) and risk factors (red) of allergic multimorbidity at 
school age [of a model selected according to AICc]. Family- allergy- score is standardized to have SD = 1. Early- age- symptoms is in the range 
1– 3 and counts the number of allergic symptoms (of allergic rhinitis, eczema, asthma) observed before age 2. All the remaining variables are 
dichotomous. The OR for family- allergy- score shows the multiplicative effect for each standard deviation, and somewhat similarly, the OR 
for early- age symptoms shows the multiplicative effect of each such symptom that is present. The factors shown are the ones present in a 
multivariate logistic model that maximizes the AICc model selection criterion
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day- care were independently protective for multimorbidity, whereas 
the family- allergy- score, caesarean- birth and early- age- symptoms 
posed a risk. The low occurrence of caesarean birth in Madrid is ex-
plained by the recruitment in the maternity ward where scheduled 
c- sections were absent (Table 2). Note that this deviation does not 
change the modelling result: in a model without Madrid, AICc selects 
the same six covariates as the full data model, with very similar esti-
mated odds ratios (S5).
The AICc procedure selects many of the same covariates for 
individual diseases (Figure 4). Day care provides a protective ef-
fect against asthma and allergic rhinitis, and the same applies to 
having older siblings. Female sex lowers the risk for both asthma 
and allergic rhinitis, but interestingly, it increased the risk for ec-
zema. Caesarean birth increased the risk only for asthma, but not 
for the other two allergic diseases. Smoking during pregnancy 
was included in the asthma model according to the AICc value 
as a risk factor. Finally, both high family- allergy- score and many 
early- age- symptoms are positively related to all three individual 
diseases.
All the other covariates listed in Section 2.3, mothers- age, parent- 
education, antibiotics- at- birth, cows- milk- in- first- week, breastfeeding, 
vitamin- D supplementation, pets- at- home, smoking- at- home, live- on- 
a- farm and mould in the house, were not selected into the models, 
neither for multimorbidity nor for any of the individual diseases. Of 
these variables, live- on- a- farm had the largest estimated effect, but 
the statistical power is low as indicated by a wide confidence interval 
(OR = 0.67, 95% CI 0.26– 1.71).
Models including only specific early- age symptoms were also 
considered. AICc selected early symptoms of both allergic rhinitis 
and eczema as predictors of school- age allergic multimorbidity by 
themselves, but not wheezing. However, when combined with one 
or both of the other two symptoms, wheezing increased the es-
timated risk, and it was also selected as a predictor of school- age 
asthma (Table S7).
Current heavy traffic exposure was identified as a risk factor for 
asthma, but not for the other two diseases (Table S8).
3.4  |  Consistency of the statistical model
To check the consistency of the modelling, multimorbidity models 
with each covariate as the only variable apart from centre effect 
were constructed. Table S2 shows the odds ratios and AICc values 
for these models and some additional models, including the final 
6- variable model of Figure 3. The results were consistent. To further 
check the stability of the results, the final model was fitted 8 times, 
each time leaving out one centre, and again, the results were consist-
ent (Tables S4 and S5).
To further check the sanity of the models, and to demonstrate 
that the multiplicative effect of the number of predictive early- age 
symptoms was realistic, we analysed two examples: there were 176 
children with two early- age symptoms. According to the model, the 
odds for these children was increased by a factor of 2.722 = 7.4. The 
model can be used to predict the rate of allergic multimorbidity at 
school age among these children (adjusting for all the other vari-
ables). Such computation predicts 46.7 children, while the actual 
count is 47. A similar investigation for all three early- age symptoms 
gives 38 children, 17 of which are multimorbid, while the model pre-
dicts 19.3.
4  |  DISCUSSION
4.1  |  Current study prevalence and comparison 
with other studies
In our study with children aged 6– 10 years, allergic rhinitis and ec-
zema were more common than asthma. There was considerable 
difference between the study centres with allergic multimorbidity 
(two or more allergic diseases) ranging from 1.2% in Athens to 10.9% 
in Madrid. We did not see any clear geographical prevalence gradi-
ent across the participating European centres, such as from north 
to south or west to east, as found in a previous population- based 
cross- sectional evaluation.15 While other studies that we considered 
F I G U R E  4  Odds ratios and 95% confidence intervals for covariates that are predictors for one or more of the individual diseases 
considered in the study (secondary outcomes). Covariates for which the confidence intervals do not contain 1 are coloured green if the 
factor is protective and red if it poses a risk. Confidence intervals of variables that are not selected into a corresponding model are shown in 
orange. See also explanations in the caption of Figure 3
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defined multimorbidity also as having at least two of asthma, aller-
gic rhinitis and eczema, they sometimes used different definitions 
of the individual diseases, however often based on original ISAAC 
questions.8
In the Swedish BAMSE birth cohort study in Stockholm, about 
12 years before our study, the prevalences at 8 years were simi-
lar with 7.1%, 14.7%, 17.0% and 5.5% for asthma, allergic rhinitis, 
eczema and allergic multimorbidity, respectively;3,16 however, the 
Scandinavian mainland was not part of our study. In the rural Isle 
of Wight study (UK), multimorbidity in 4- and 10- year- old children 
was 7.8% and 10.5%, respectively, in 1993– 199917 as compared to 
9.7% in 7.9- year- old children in Southampton in the current study. 
In that study, the prevalence of allergic multimorbidity increased 
further to 15.8% in 18- year- olds. A recent Polish cross- sectional 
multicentre study found 10.7% of 6- to 7- year- old children having 
allergic multimorbidity,18 compared with the current study prev-
alence in Lodz, 9.8%. In the Dutch PIAMA birth cohort, including 
many rural areas, the published asthma prevalence for 8- year- old 
children in 2003– 2004 was 7.2%,19 thus lower than the 11.4% for 
the city of Amsterdam in the current study. Study prevalence of 
allergic multimorbidity in Berlin was similar to the risk- enriched 
population- based German MAS study, about 20 years earlier, 
when compared separately for high- risk and low- risk children 
(Table S6).1
In 116,863 children at 6– 7 years from 22 affluent and non- 
affluent countries that participated in phase III of the global cross- 
sectional International Study of Asthma and Allergies in Childhood 
(ISAAC), performed 2000– 2003, the prevalence for asthma was 
9.7%, for allergic rhinitis 8.9%, for eczema 7.3% and for allergic 
multimorbidity 5.0%,20 somewhat lower than our findings across 
Europe.
The differences in definitions of the allergic diseases between 
studies and study settings make it hard to draw conclusions on 
whether allergic multimorbidity is a waxing problem in Europe. 
However, our prevalence estimates ranging up to 11% in Madrid 
considering only the three most common allergic diseases shows 
that allergic multimorbidity is a common problem for many primary 
school- aged children in Europe.
In our assessments in children up to 2.5- year- olds, Athens 
(Greece) had the second lowest wheezing prevalence and lowest 
prevalence of confirmed food allergy,21– 23 and now has the lowest 
study prevalence of all three single diseases, as well as allergic mul-
timorbidity. It also has, by far, the lowest estimate for school- age 
food allergy.6 However, Madrid, also in Mediterranean Europe, has 
the highest observed prevalence of both allergic multimorbidity and 
eczema, and high percentage for the other two diseases.
The considerable differences between cities (Section 3.1) evi-
dently cannot be explained by the geographical locations. Genetic 
susceptibility and/or environmental factors such as diet may play a 
role. The relatively low prevalence in Reykjavik could be partly due 
to the widespread supplementation of fish oil to infants,12 or possi-
bly less pollution.
4.2  |  Risk factors
As expected, family- allergy- score had a large effect not only on single 
allergic diseases but also on allergic multimorbidity. Interestingly, al-
lergic family history appeared to influence the occurrence of eczema 
less than respiratory allergy.
Also, as expected, the best predictor for allergic multimor-
bidity at school age were early- age- symptoms of allergic diseases. 
Early- age symptoms are of course not a risk factor, strictly speak-
ing. Multimorbidity models without early- age- symptoms give odds 
ratios for the other factors that are comparable to those of the 
full model (Figure 3, Table S2). The same holds for individual dis-
eases (data not shown). If the aim is to predict school- age allergic 
diseases, one would use all available data, including the early- 
age- symptoms, but if the aim is to study the causal pathway, this 
variable should be excluded.
Being a girl is protective against allergic multimorbidity, asthma 
and allergic rhinitis at school age, but carries a risk for eczema. These 
findings confirm results from MAS, PARIS, and BAMSE.1,10,16,24 In 
MAS, boys with eczema had more allergic multimorbidity than girls 
with eczema. This was confirmed by our study, 40% and 30% for 
boys and girls, respectively (p = .07; data not shown). The PARIS 
study also showed boys to be at higher risk of allergic sensitization 
to aeroallergens and food allergens, and at much higher risk of being 
multisensitized.
Pregnancy- smoking was not found to affect allergic multimor-
bidity; however, according to the AICc criterion, it is a risk factor for 
primary school- age asthma (OR = 1.54, 95% CI = 0.99– 2.38). This 
is in agreement with multiple other studies, where smoking during 
pregnancy increased the risk for early- life wheezing and school- 
age asthma, even more than other tobacco smoke exposure.25– 30
Figure 4 indicates that pregnancy smoking primarily affects non- 
atopic asthma,28,31 and the same applies to caesarean- birth, which 
is a risk factor for multimorbidity and asthma, but not for allergic 
rhinitis or eczema. The result for asthma confirms findings of a re-
cent meta- analysis, albeit with considerable statistical heterogene-
ity, with mainly retrospective and cross- sectional studies, showing 
an increased asthma risk by caesarean birth.32 Not included in this 
meta- analysis were two separate evaluations of long- term prospec-
tive population- based birth cohorts, focusing on asthma and allergy, 
which did not find association between caesarean birth and asthma 
at age 1533 and 20 years.30
In previous studies, having older siblings and day- care attendance 
were both protective for respiratory allergic diseases at school 
age.20,34,35 The protective effects of natural birth, older siblings and 
day care attendance have been explained by the increased expo-
sure to protective bacteria in infancy,36,37 whereas the protection 
by older siblings was also hypothesized of being an in utero immune 
priming effect.35
The negative effect of current traffic on asthma is consistent 
with earlier findings (Table S7).19 We did not have accessible infor-
mation on traffic at early age.
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4.3  |  Allergic multimorbidity is a disease in its 
own right
Several studies show that allergic multimorbidity can be considered 
as a special disease.2,16 This is supported by a genetic study.38
In our study, asthma concurrent with allergic rhinitis and/or 
eczema accounted for about half of the asthma cases, 3.9% (2.9% 
+1.0%; Table 1) out of 8.1%, approximately twice as often as would 
be expected if the diseases were independent. If they were inde-
pendent, the prevalence of all three being concurrent would be 
0.13% (0.081 × 0.133 × 0.120 = 0.0013), whereas the actual cohort 
prevalence of the triple multimorbidity is ten times higher, 1.3% 
(Table 1).
We concentrated on allergic diseases at the age around 8 years; 
however, the coexistence of the diseases may have developed in 
different patterns from infancy. A study using machine learning 
identified 8 such patterns, leading to different combinations of the 
diseases at school age.39 A study on atopic endotypes in childhood 
identified four patterns of disease development.40
4.4  |  Strengths and weaknesses of the study
The current study involves multiple countries from all climatic re-
gions in Europe, it uses prospectively collected data from birth to 
school age by the same standardized methods, and it is to date the 
largest such single study. It had sufficient statistical power to exam-
ine potential risk factors in a single model. To a certain extent, some 
of these risk and protective factors are modifiable (pregnancy smok-
ing, caesarean birth, day care and traffic exposure). Being a prospec-
tive study, early- life risk factors can be determined without relying 
on long- term memory of the parents.
However, the generalizability of the cohort to the whole pop-
ulations has not been formally assessed and may be limited. 
Furthermore, a considerable number of children were lost to fol-
low- up after 6– 10 years since birth, possibly exaggerating the 
estimated multimorbidity percentage. It is also possible that the 
differences in loss between centres introduce bias in the estimates 
from the regression; however, it is not easy to analyse the nature of 
this bias. Also, several interesting and probably important potential 
early- life factors are not considered, for example paracetamol and 
antibiotic use, diet and IgE sensitization. The BAMSE birth cohort, 
the Isle of Wight study and PARIS birth cohort showed food and 
airborne sensitization in infancy to be risk factors for later allergic 
multimorbidity.3,17,24
5  |  CONCLUSIONS
Allergic multimorbidity should be considered as a relevant chronic 
childhood condition in Europe and probably around the globe. 
Importantly, some of the associated early- life factors that this study 
identified are modifiable and thus can be considered for prevention 
strategies. Future research on allergic diseases should focus on in-
dividuals with multimorbidity, for better understanding of the un-
derlying mechanisms, with the ultimate aim for improved disease 
management. Knowledge gaps include the age bracket from child-
hood to adulthood, associations with other allergic and non- allergic 
comorbidities, and effects of the diseases on quality of life in fami-
lies with allergic multimorbidity. The currently ongoing COVID- 19 
pandemic will further direct the focus on the link between viral in-
fections and chronic respiratory diseases and allergies.
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